

Various Approaches and Future Prospective for Therapies for Diabetes: A Review

Yogesh Tiwari^{1*}, Preeti Kothiyal¹, Sayantan Mukhopadhyay²

¹*School of Pharmacy and Research Dev Bhoomi Uttarakhand University, Dehradun, Uttarakhand, India.*

²*College of Pharmacy, Shivalik campus, Dehradun, Uttarakhand, India.*

Received: 09th May, 2024; Revised: 02nd June, 2024; Accepted: 15th July, 2024; Available Online: 31st August, 2024

ABSTRACT

The global prevalence of diabetes mellitus disease marked by increased blood glucose levels, has reached epidemic proportions. This review provides a comprehensive assessment of the current landscape of diabetes therapies and outlines future prospects for improving the management and treatment of this condition. The current scenario highlights a multifaceted approach to diabetes management, with a focus on lifestyle interventions, oral antidiabetic drugs, insulin therapy, and emerging technologies like continuous glucose monitoring and closed-loop systems. While these approaches have significantly improved the lives of people with diabetes, several challenges persist. These include medication adherence, hypoglycemia risk, and the financial burden of diabetes care. Innovative treatments that improve glucose regulation, improve cardiovascular health, and help patients lose weight—like SGLT-2 inhibitors and GLP-1 receptor agonists—have showed promise in treating these issues. The future prospects for diabetes therapies are exciting, with ongoing research into cell-based therapies, including pancreatic islet transplantation and stem cell-derived beta cells. Personalized medicine approaches, driven by genetics and artificial intelligence, hold the potential to optimize treatment regimens and predict individual responses to various therapies. Furthermore, advancements in telemedicine and digital health technologies will enhance patient self-management and remote monitoring.

Keywords: Immune based therapies, Artificial pancreas, Autoimmune, Diabetes mellitus.

International Journal of Pharmaceutical Quality Assurance (2024); DOI: 10.25258/ijpqa.15.3.88

How to cite this article: Tiwari Y, Kothiyal P, Mukhopadhyay S. Various Approaches and Future Prospective for Therapies for Diabetes: A Review. International Journal of Pharmaceutical Quality Assurance. 2024;15(3):1671-1677.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Diabetes mellitus, a chronic metabolic disease that is complicated and marked by high blood glucose, has become a significant global public health concern. In addition to giving a brief review of the state of diabetes therapy today, this introduction also gives an optimistic outlook for the future of diabetes care and treatment.¹⁻⁶

The Diabetes Epidemic: A Growing Global Concern

Diabetes has become a global epidemic that affects individuals of all ages, genders, and socioeconomic status. The number of adults with diabetes is predicted to rise to an astounding 700 million by 2045, from 463 million in 2019. This information is received from the International Diabetes Federation (IDF). Diabetes is a serious health risk that puts a heavy financial strain on healthcare systems and society at large, thus it is alarming that its incidence is steadily rising.

The consequences of uncontrolled diabetes are multifaceted and far-reaching, including a heightened risk of cardiovascular disease, kidney complications, vision

impairment, and lower limb amputations. Moreover, diabetes raises the chance of dying; impairing the overall quality of life of affected ones.

Current Approaches to Diabetes Management:

The dynamic and multidimensional process of managing diabetes involves pharmacological medications, lifestyle modifications, and close observation in order to attain and maintain glycemic control. These strategies seek to improve general health, lessen the chance of complications, and raise the standard of living for those who have diabetes.⁷⁻¹⁵

Lifestyle Interventions

- Dietary modifications are pivotal in diabetes management, with an emphasis on carbohydrate control, portion management, and the consumption of nutrient-dense foods.
- Regular exercise plays a vital role in improving insulin sensitivity and glycemic control. It is a cornerstone of diabetes self-management.

*Author for Correspondence: yogeshtiwari@gmail.com

Pharmacological Therapies

- To lower blood glucose levels, a variety of oral drugs are available, like metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, and thiazolidinediones.
- People with advanced type 2 diabetes and those with type 1 diabetes require insulin replacement therapy. Different insulin regimens offer possibilities for customized treatment, including long-acting and basal-bolus formulations.

3. Continuous Monitoring and Technological Advances

- Traditional finger stick glucose testing has evolved into continuous glucose monitoring (CGM) systems offer trending and real-time glucose assessments.
- Insulin delivery methods, including insulin pumps, have become increasingly precise, offering better insulin dosing and management.

The future of diabetes therapy is replete with promise, as researchers, clinicians, and the pharmaceutical industry collaborate to enhance the quality of care, reduce complications, and elevate the overall well-being of individuals living with diabetes.

Cell-Based Therapies

Islet transplantation, a procedure involving the transplantation of insulin-producing islet cells into the liver, has exhibited the potential to achieve insulin independence in some individuals with type 1 diabetes.¹⁶⁻²¹

Stem cell-derived beta cells

Advancements in stem cell research offer the possibility of generating insulin-producing beta cells that can replace damaged or dysfunctional cells in individuals with diabetes.

Personalized Medicine

Genetics and genomics

Progress in genetic research enables the identification of genetic markers linked to diabetes risk and responses to treatment. Personalized medicine approaches have the potential to customize a patient's course of care according to their genetic profile.

Artificial intelligence

The application of machine learning and artificial intelligence is poised to analyze patient data, predict responses to therapies, and optimize treatment regimens, transforming diabetes care into a more precise and individualized field.

Digital Health Technologies

Telemedicine and remote monitoring

Enhancing accessibility and decreasing the need for frequent in-person clinic visits is possible by integrating telemedicine and remote monitoring applications, which enable people to receive care and support from the comfort of their own homes.

Mobile apps and wearable devices

Mobile applications and wearable devices provide tools for monitoring blood glucose, diet, exercise, and medication

adherence, empowering patients to actively engage in self-management.

Immunotherapy

Ongoing research is exploring the development of immunotherapy designed to modify the immune response responsible for destroying insulin-producing cells in type 1-diabetes. These therapies hold the potential to slow or halt the progression of the disease.

Diabetes represents a global health crisis, with its prevalence continuing to rise. The current approach to diabetes management combines lifestyle interventions, pharmacological therapies, and technological advancements, which have improved the lives of individuals with diabetes. However, challenges such as adherence, hypoglycemia, and financial burdens persist. Yet, the future of diabetes therapy is filled with promise, featuring cell-based therapies, personalized medicine, digital health technologies, and immunotherapy.²²⁻²⁶

Insulin Replacement Therapy

One of the most important and frequently life-saving treatments for people with diabetes, especially those with diabetes (type 1) and some cases of advanced diabetes is insulin replacement therapy. In this therapy, endogenous insulin production is either absent or insufficient, and insulin a hormone that the pancreas typically produces is administered to control blood glucose levels. The body needs insulin in order to use glucose, which is the main energy source for cells.

Here are the key aspects of insulin replacement therapy²⁷⁻³²

Indications

- *Type 1 diabetes*

Individuals with type 1 diabetes, in which the pancreas's beta cells that make insulin are degraded or destroyed by the immune system, need lifelong insulin replacement therapy since their pancreas is unable to manufacture insulin.

- *Advanced Type 2-diabetes*

In some cases of type 2-diabetes, when oral antidiabetic medications are no longer sufficient to control blood sugar, insulin therapy may be initiated.

Types of insulin

- *Rapid-acting insulin*

Insulin lispro and insulin as part are examples of rapid-acting insulins that immediately reduce blood sugar levels after meals. Usually, they are injected right before or after a meal.

- *Short-acting insulin*

One type of insulin that acts quickly is regular insulin. In comparison to rapid-acting insulin, it acts more slowly and is usually taken before meals.

- *Intermediate acting insulin*

Is known as neutral protamine Hagedorn insulin. It is frequently used in conjunction with other forms of insulin because of its longer duration of action.

- *Long-acting insulin*

Insulins like glargine and detemir have a prolonged duration of action, providing basal (background) insulin coverage. They are typically taken once daily to maintain stable blood sugar levels between meals and throughout the night.

Insulin Delivery Methods

Subcutaneous injections

Insulin is most frequently given via subcutaneous injections using insulin pumps, pens, or syringes.

Insulin Pumps: are small devices that provide people with the ability to bolus (administer) extra insulin before meals as needed. Insulin pumps can constantly supply basal insulin. This technique enables flexibility and accurate dosage.

Insulin Regimens

Basal-bolus regimen

The basal-bolus regimen entails the administration of long-acting basal and short-acting or rapid-acting bolus insulin's. Bolus insulin is taken before to meals to offset the spike in blood sugar that occurs with eating, while basal insulin maintains a constant baseline level.

Premixed Insulin's

These insulins combine a fixed ratio of short-acting and intermediate-acting insulins in one injection. They are convenient for some individuals with type 2-diabetes.

Individualization

Each diabetic patient has very specialized needs that are met by insulin therapy. When choosing the kind, dosage, and timing of insulin administration, various factors are taken into account, including age, lifestyle, food, degree of exercise, and general health.

Monitoring

For the purpose of glycemic management and insulin dosage adjustments, routine blood glucose monitoring is crucial. Real-time blood sugar data is provided by continuous glucose monitoring (CGM) devices, which assist people in making educated decisions on insulin dosage.

Challenges and Considerations

Hypoglycemia

One of the primary risks of insulin therapy is hypoglycemia, or low blood sugar. It can occur if insulin doses are too high or if there's a mismatch between insulin and carbohydrate intake.

Weight Gain

Some individuals experience weight gain with insulin therapy, which can be a concern, particularly for those with type 2-diabetes.

Education and Self-Management

Successful insulin therapy requires education and self-management skills to adjust doses based on factors like exercise, illness, and dietary changes.

Future perspectives on Insulin Replacement Therapy

Insulin replacement therapy, a mainstay in the treatment of diabetes, has come a long way since its discovery nearly a century ago. However, the landscape of insulin therapy continues to evolve, and future perspectives hold exciting prospects for improved effectiveness, convenience, and personalized care. Here are some key future directions for insulin replacement therapy.³³⁻³⁷

Advanced Insulin Formulations

Ultra-rapid-acting insulins

Research is ongoing to develop insulins that mimic the rapid response of the body's natural insulin secretion.³⁸ These ultra-rapid-acting insulins could provide more precise control over post-meal blood glucose spikes, offering greater flexibility in meal timing.

Inhaled insulin

As an alternative to subcutaneous injections, inhaled insulin formulations like Afrezza are available. In the future, there might be more convenient, quick-acting, and long-lasting inhaled insulin solutions.

Smart Insulin and Glucose-Sensing Technologies

Smart insulins

These are insulin formulations that can respond dynamically to changes in blood glucose levels. They are designed to activate or deactivate in response to glucose fluctuations, reducing the risk of hypoglycemia. Research into smart insulin continues to advance, and their development could revolutionize insulin therapy.

Closed-loop systems

Referred as artificial pancreas systems, integrate insulin pumps with continuous glucose monitoring.³⁹⁻⁴¹ By using CGM data to alter doses in real time, they hope to automate the delivery of insulin. These algorithms and technologies are developing into more accurate and user-friendly systems.

Personalized Insulin Therapy

Genetic and pharmacogenomic approaches

Healthcare professionals can now tailor insulin regimens to each patient's unique genetic profile because to developments in pharmacogenomics and genetics. The best kind, amount, and timing of insulin for each patient can be ascertained with the aid of this personalized medicine method.

Long-Acting Insulins

Once-weekly insulins

Research is ongoing to develop long-acting insulins that only need to be administered once a week, offering a more convenient treatment option for some individuals with diabetes. These insulins aim to provide stable basal coverage over an extended period.

Cell-Based Therapies

Stem cell-derived insulin-producing cells

Is investigating the use of stem cells to produce beta cells that can produce insulin and be injected into the body. This strategy may be helpful for those with type 1 diabetes who don't have functioning beta cells.

The future of insulin replacement therapy is marked by exciting developments, with the potential for ultra-rapid-acting insulins, smart insulins, personalized medicine, cell-based therapies, telemedicine, AI-driven management, and improved insulin delivery methods. These innovations hold the promise of providing more effective, patient-centric and accessible diabetes care, ultimately improving the lives of millions of individuals living with diabetes. However, the translation of these advancements into clinical practice and the equitable access to these therapies are essential challenges to address in the years to come.

Sodium-glucose Co-transporter 2 Inhibitors

A class of drugs is sodium-glucose co-transporter 2 (SGLT-2) inhibitors is used to treat type 2 diabetes. These medications upraise the amount of glucose excreted in the urine by lowering the kidneys' ability to absorb glucose by targeting a certain protein. This method of action has several benefits for the kidneys and cardiovascular system in addition to lowering blood glucose levels. These are some important SGLT-2 inhibitor characteristics.⁴²⁻⁴⁷

Mechanism of Action

An enzyme known as SGLT-2 is located in the kidneys' proximal convoluted tubules and is the target of SGLT-2 inhibitors. Reabsorbing glucose from the urine and returning it to the bloodstream is the function of this protein. Through SGLT-2 inhibition, these medications stop glucose from being absorbed again, resulting in its excretion in the urine. Blood glucose levels decrease as a result.

Common SGLT-2 Inhibitors

There are a number of SGLT-2 inhibitors on the market, such as: empagliflozin (Jardiance) dapagliflozin (Farxiga) canagliflozin (Invokana)

Effects on Blood Glucose Control

SGLT-2 inhibitors work by encouraging the excretion of extra glucose in the urine, which lowers blood glucose levels. To enhance glycemic control with type 2 diabetes, they can be taken either alone or in conjunction with other diabetic drugs like insulin or metformin.

Cardiovascular Benefits

According to recent research, SGLT-2 inhibitors are beneficial for the cardiovascular system and can lower the risk of heart attacks, strokes, and cardiovascular death, especially in patients with multiple risk factors or established cardiovascular disease.

Renal Benefits

Additionally, SGLT-2 inhibitors benefit the kidneys. In those with type 2 diabetes, they can lower the risk of end-stage renal disease, or kidney failure, and decrease the advancement of diabetic kidney disease. A novel method of treating type 2 diabetes is provided by a class of drugs called SGLT-2 inhibitors, which encourage the elimination of extra glucose in the urine. They also have positive effects on the kidneys and cardiovascular system in addition to better blood glucose control. As with any drug, it's critical to collaborate closely with a medical professional to identify the best course of action and to keep an eye out for any possible interactions or adverse effects.

Future Prospective for Therapies for Diabetes

The future perspectives for therapies for diabetes are characterized by ongoing innovation, increased personalization, and the quest for more effective, convenient, and accessible treatments. Here are some key areas of development and trends in the field of diabetes therapies.⁴⁸⁻⁵²

Personalized Medicine

Advances in genomics, pharmacogenomics, and precision medicine will enable healthcare providers to tailor diabetes treatments to individual genetic and molecular profiles. This approach will optimize therapy efficacy while minimizing side effects.

Artificial Pancreas and Closed-Loop Systems

Artificial pancreas devices will continue to be developed and improved. As these systems develop, the burden of managing diabetic self-care will be lessened by offering more automated and accurate blood glucose control.

Innovative Insulin Formulations

Research will lead to the development of ultra-rapid-acting and longer-acting insulin formulations. These innovations will enhance glycemic control and provide greater flexibility in insulin dosing and meal planning.

Non-Invasive Glucose Monitoring

The search for minimally invasive or non-invasive glucose monitoring techniques will not stop. Painful finger stick testing will become less necessary thanks to technologies like wearables, patches, and contact lenses that sense glucose.

Immune-Based Therapies

Ongoing research into the role of the immune system in type 1 diabetes may lead to immune-based therapies that can modify or suppress the autoimmune response, potentially slowing or halting the progression of the disease.

Artificial Intelligence and Machine Learning

AI-driven algorithms will play an increasing role in analyzing CGM data, insulin dosing, and dietary information. These technologies will provide real-time recommendations for optimizing insulin therapy and improving overall glycemic control.

Advanced Glucose-Lowering Medications

New drugs for the treatment of diabetes include SGLT-2 inhibitors, GLP-1 receptor agonists, and incretin-based treatments. These medications have advantages for the kidneys and cardiovascular systems in addition to lowering blood sugar. The future of diabetes therapies holds great promise, with a focus on personalization, innovation, and improved patient outcomes.⁵³⁻⁵⁵ The integration of technology, AI, and advanced medications will continue to enhance diabetes management, making it more convenient and effective. However, addressing the economic and ethical considerations surrounding these advancements is equally crucial to ensure equitable access to the benefits of these evolving therapies for individuals living with diabetes worldwide.

DISCUSSION

Insulin Replacement Therapy

A vital component of diabetes care is insulin replacement therapy, especially for people with type 1 diabetes who are unable to manufacture insulin. It is essential for controlling blood sugar levels and averting diabetic complications.⁵⁶ The emergence of ultra-rapid-acting insulins, tailored insulin therapy, and smart insulins holds promise for improving its efficiency and practicality.

Sodium-Glucose Co-Transporter 2 Inhibitors

In order to treat type 2 diabetes, SGLT-2 inhibitors have revolutionized the field. In order to improve glycemic control, assist the cardiovascular system, and aid in weight loss, they function by encouraging the excretion of glucose in the urine. They also hold potential in managing heart failure. However, they are not without side effects, such as an increased risk of genital infections and, rarely, diabetic ketoacidosis (DKA).

Future Perspectives for Diabetes Therapies

The future of diabetes therapies holds exciting prospects, with a strong emphasis on personalized medicine, technological advancements, and novel treatment approaches. Personalized medicine based on genetic and molecular profiles will allow more targeted treatment plans. Innovations in insulin formulations, glucose monitoring, and artificial pancreas systems promise to improve glycemic control and quality of life for individuals with diabetes.⁵⁷ Immune-based therapies may offer potential solutions for type 1 diabetes, while behavioral interventions and comprehensive care remain integral in managing the condition.

In conclusion, these studies and topics underscore the ongoing evolution of medical therapies, ranging from hormone-based treatments for diabetes and growth disorders to the groundbreaking potential of immune therapies for cancer.⁵⁸ The future of these therapies is marked by increased personalization, technological advancements, and a prioritize enhancing patient outcomes and standard of living. It's essential that ethical, regulatory, and accessibility considerations remain a central part of these advancements to ensure equitable access and responsible use of these innovative treatments.

CONCLUSION

In conclusion, the studies and topics discussed here collectively highlight the ever-evolving landscape of medical therapies and their potential to significantly impact patient care and outcomes.

Insulin replacement therapy remains an essential and evolving treatment for diabetes. With the development of ultra-rapid-acting insulins, smart insulins, and the personalized approach, patients with diabetes can look forward to more effective and convenient ways of managing their condition.

Inhibitors of the sodium-glucose co-transporter 2 have completely changed how type 2 diabetes is treated. They provide advantages for the kidneys and cardiovascular system in addition to lowering blood sugar.⁵⁹ But it's important to be aware of possible adverse effects like infections and diabetic ketoacidosis.

Future perspectives for diabetes therapies reveals a promising horizon for diabetes management. Personalized medicine, technological advancements, and novel treatment approaches will transform the lives of individuals with diabetes. The emphasis on patient-centric care and comprehensive interventions is vital for achieving better outcomes.

In summary, these studies and topics collectively underscore the dynamic nature of medical research and the continuous quest to improve patient care.⁶⁰ The future holds exciting possibilities for more effective, personalized, and accessible therapies, with a strong focus on patient well-being and the responsible use of innovative treatments. These advancements not only offer hope but also reaffirm the importance of ethical, regulatory, and equitable considerations in the ever-advancing field of medicine.

AUTHORS CONTRIBUTIONS

All data collection done by corresponding authors and other authors are done the formatting and data analysis.

REFERENCES

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *New England journal of medicine*. 1993 Sep 30;329(14):977-86.
2. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *New England Journal of Medicine*. 2005 Dec 22;353(25):2643-53.
3. Cryer PE. Hypoglycemia: the limiting factor in the management of IDDM. *Diabetes*. 1994 Nov 1;43(11):1378-89.
4. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. *Diabetes*. 1974 May 1;23(5):389-96.
5. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). *Hormone and metabolic research= Hormon-und Stoffwechselforschung= Hormones et metabolisme*. 1977 Jan 1:23-33.

6. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W, Schipper H, Gander R. Clinical control of diabetes by the artificial pancreas. *Diabetes*. 1974 May 1;23(5):397-404.
7. Pfeiffer EF, Thum C, Clemens AH. The artificial beta cell—a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). *Hormone and Metabolic Research*. 1974;6(05):339-42.
8. Kerner W, Thum C, Beischer W, Clemens AH, Pfeiffer EF. Attempts at perfect normalization of glucose tolerance test of severe diabetics by artificial beta cell. *Hormone and Metabolic Research*. 1976;8(04):256-61.
9. Kraegen EW, Whiteside R, Bell D, Chia YO, Lazarus L. Development of a closed-loop artificial pancreas. *Hormone and Metabolic research. Supplement Series*. 1979 Jan 1(8):38-42.
10. Mirouze J, Selam JL, Pham TC, Cavadore D. Evaluation of exogenous insulin homeostasis by the artificial pancreas in insulin-dependent diabetes. *Diabetologia*. 1977 May;13:273-8.
11. Shichiri M, Kawamori R, Hakui N, Asakawa N, Yamasaki Y, Abe H. The development of wearable-type artificial endocrine pancreas and its usefulness in glycaemic control of human diabetes mellitus. *BiomedicaBiochimica Acta*. 1984 Jan 1;43(5):561-8.
12. Goriya Y, Kawamori R, Shichiri M, Abe H. The development of an artificial beta cell system and its validation in depancreatized dogs: the physiological restoration of blood glucose homeostasis. *Medical Progress Through Technology*. 1979 Jun 1;6(3):99-108.
13. Kawamori R, Shichiri M, Goriya Y, Yamasaki Y, Shigeta Y, Abe H. Importance of insulin secretion based on the rate of change in blood glucose concentration in glucose tolerance, assessed by the artificial beta cell. *European Journal of Endocrinology*. 1978 Feb;87(2):339-51.
14. Jazowski SA, Winn AN. The role of the FDA and regulatory approval of new devices for diabetes care. *Current Diabetes Reports*. 2017 Jun;17:1-0.
15. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. *Diabetes*. 2011 Nov 1;60(11):2672-82.
16. Thabit H, Hovorka R. Closed-loop insulin delivery in type 1 diabetes. *Endocrinology and Metabolism Clinics*. 2012 Mar 1;41(1):105-17.
17. Kumareswaran K, Evans ML, Hovorka R. Closed-loop insulin delivery: towards improved diabetes care. *Discovery medicine*. 2012 Feb 23;13(69):159-70.
18. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. *Nature Reviews Endocrinology*. 2011 Jul;7(7):385-95.
19. Elleri D, Dunger DB, Hovorka R. Closed-loop insulin delivery for treatment of type 1 diabetes. *BMC medicine*. 2011 Dec;9:1-9.
20. McCall AL, Farhy LS. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. *Minerva endocrinologica*. 2013 Jun;38(2):145.
21. Renard E, Cobelli C, Kovatchev BP. Closed loop developments to improve glucose control at home. *Diabetes research and clinical practice*. 2013 Nov 1;102(2):79-85.
22. Renard E, Costalat G, Chevassus H, Bringer J. Artificial β -cell: clinical experience toward an implantable closed-loop insulin delivery system. *Diabetes & metabolism*. 2006 Dec 1;32(5):497-502.
23. Renard E. Clinical experience with an implanted closed-loop insulin delivery system. *ArquivosBrasileiros de Endocrinologia&Metabologia*. 2008;52:349-54.
24. Keith-Hynes P, Guerlain S, Mize B, Hughes-Karvetski C, Khan M, McElwee-Malloy M, Kovatchev BP. DiAs user interface: a patient-centric interface for mobile artificial pancreas systems.
25. Dassau E, Jovanovic L, Doyle III FJ, Zisser HC. Enhanced 911/global position system wizard: a telemedicine application for the prevention of severe hypoglycemia—monitor, alert, and locate. *Journal of diabetes science and technology*. 2009 Nov;3(6):1501-6.
26. Rigla M, Hernando ME, Gómez EJ, Brugués E, García-Sáez G, Torralba V, Prados A, Erdozain L, Vilaverde J, De Leiva A. A telemedicine system that includes a personal assistant improves glycemic control in pump-treated patients with type 1 diabetes. *Journal of diabetes science and technology*. 2007 Jul;1(4):505-10.
27. Schade DS. Intensive insulin therapy. *Excerpta Medica*; 1983.
28. Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ. Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. *Diabetes care*. 1981 Mar 1;4(2):311-8.
29. Updike SJ, Shults MC, Busby M. Continuous glucose monitor based on an immobilized enzyme electrode detector. *The Journal of Laboratory and Clinical Medicine*. 1979 Apr 1;93(4):518-27.
30. Updike SJ, Shults M, Ekman B. Implanting the glucose enzyme electrode: problems, progress, and alternative solutions. *Diabetes Care*. 1982 May 1;5(3):207-12.
31. Updike SJ, Hicks GP. The enzyme electrode. *Nature*. 1967 Jun 3;214(5092):986-8.
32. Johnson KW, Mastrototaro JJ, Howey DC, Brunelle RL, Burden-Brady PL, Bryan NA, Andrew CC, Rowe HM, Allen DJ, Noffke BW, McMahan WC. In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue. *Biosensors and Bioelectronics*. 1992 Jan 1;7(10):709-14.
33. Mastrototaro JJ. The MiniMed continuous glucose monitoring system. *Diabetes technology & therapeutics*. 2000 Dec 1;2(1, Supplement 1):13-8.
34. Tamborlane WV, Sherwin RS, Genel M, Felig P. Outpatient treatment of juvenile-onset diabetes with a preprogrammed portable subcutaneous insulin infusion system. *The American Journal of Medicine*. 1980 Feb 1;68(2):190-6.
35. Sherwin RS, Tamborlane WV, Genel M, Felig P. Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump. *Diabetes care*. 1980 Mar 1;3(2):301-8.
36. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Federici MO, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. *Physiological measurement*. 2004 Jul 22;25(4):905.
37. Cobelli C, Dalla Man C, Sparacino G, Magni L, De Nicolao G, Kovatchev BP. Diabetes: models, signals, and control. *IEEE reviews in biomedical engineering*. 2009 Dec 22;2:54-96.
38. Schmidt S, Boiroux D, Duun-Henriksen AK, Frøssing L, Skyggebjerg O, Jørgensen JB, Poulsen NK, Madsen H, Madsbad S, Nørgaard K. Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience. *Journal of diabetes science and technology*. 2013 Sep;7(5):1255-64.
39. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. *Diabetes*. 2006 Dec 1;55(12):3344-50.
40. Weinzimer SA, Sherr J, Cengiz E. Reduction of post-prandial glucose excursions during closed-loop (CL) feedbackcontrolled insulin delivery with a manual priming bolus: 029. *Pediatr. Diabetes*. 2006;7(Suppl):67-8.
41. Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes

- P, Anderson SM, Brown SA, Chernavsky DR, Breton MD, Farret A, Pelletier MJ. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. *Diabetes care*. 2013 Jul 1;36(7):1851-8.
42. Castle JR, Engle JM, Youssef JE, Massoud RG, Ward WK. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
43. Cox DJ, Clarke WL, Gonder-Frederick L, Pohl S, Hoover C, Snyder A, Zimbelman L, Carter WR, Bobbitt S, Pennebaker J. Accuracy of perceiving blood glucose in IDDM. *Diabetes care*. 1985 Nov 1;8(6):529-36.
44. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. *Diabetes care*. 1987 Sep 1;10(5):622-8.
45. Bolincier J, Ungerstedt U, Arner P. Microdialysis measurement of the absolute glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in diabetic patients. *Diabetologia*. 1992 Dec;35:1177-80.
46. Hagström E, Arner P, Engfeldt P, Bolinder J. In vivo subcutaneous adipose tissue glucose kinetics after glucose ingestion in obesity and fasting. *Scandinavian Journal of Clinical and Laboratory Investigation*. 1990 Jan 1;50(2):129-36.
47. Bolinder J, Hagström E, Ungerstedt U, Arner P. Microdialysis of subcutaneous adipose tissue in vivo for continuous glucose monitoring in man. *Scandinavian journal of clinical and laboratory investigation*. 1989 Jan 1;49(5):465-74.
48. Wientjes KJ, Schoonen AJ. Determination of time delay between blood and interstitial adipose tissue glucose concentration change by microdialysis in healthy volunteers. *The International journal of artificial organs*. 2001 Dec;24(12):884-9.
49. Schoonen AJ, Wientjes KJ. A model for transport of glucose in adipose tissue to a microdialysis probe. *Diabetes technology & therapeutics*. 2003 Aug 1;5(4):589-98.
50. Voskanyan G, Keenan DB, Mastrototaro JJ, Steil GM. Putative delays in interstitial fluid (ISF) glucose kinetics can be attributed to the glucose sensing systems used to measure them rather than the delay in ISF glucose itself.
51. Rebrin K, Sheppard Jr NF, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset.
52. Basu A, Dube S, Slama M, Errazuriz I, Amezcua JC, Kudva YC, Peyser T, Carter RE, Cobelli C, Basu R. Time lag of glucose from intravascular to interstitial compartment in humans. *Diabetes*. 2013 Dec 1;62(12):4083-7.
53. Micheletto F, Dalla Man C, Kolterman O, Chiquette E, Herrmann K, Schirra J, Kovatchev B, Cobelli C. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. *Diabetes technology & therapeutics*. 2013 Oct 1;15(10):802-9.
54. Steil GM, Palerm CC, Kurtz N, Voskanyan G, Roy A, Paz S, Kandeel FR. The effect of insulin feedback on closed loop glucose control. *The Journal of Clinical Endocrinology & Metabolism*. 2011 May 1;96(5):1402-8.
55. Steil GM. Algorithms for a closed-loop artificial pancreas: the case for proportional-integral-derivative control. *Journal of diabetes science and technology*. 2013 Nov;7(6):1621-31.
56. Ellingsen C, Dassau E, Zisser H, Grosman B, Percival MW, Jovanović L, Doyle III FJ. Safety constraints in an artificial pancreatic β cell: an implementation of model predictive control with insulin on board. *Journal of diabetes science and technology*. 2009 May;3(3):536-44.
57. Gondhalekar R, Dassau E, Zisser HC, Doyle III FJ. Periodic-zone model predictive control for diurnal closed-loop operation of an artificial pancreas.
58. Van Heusden K, Dassau E, Zisser HC, Seborg DE, Doyle III FJ. Control-relevant models for glucose control using a priori patient characteristics. *IEEE transactions on biomedical engineering*. 2011 Nov 22;59(7):1839-49.
59. Dassau E, Zisser H, Harvey RA, Percival MW, Grosman B, Bevier W, Atlas E, Miller S, Nimri R, Jovanović L, Doyle III FJ. Clinical evaluation of a personalized artificial pancreas. *Diabetes care*. 2013 Apr 1;36(4):801-9.
60. Dassau E, Zisser H, Palerm CC, Buckingham BA, Jovanović L, Doyle III FJ. Modular artificial β -cell system: a prototype for clinical research. *Journal of Diabetes Science and Technology*. 2008 Sep;2(5):863-72.